Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mast Therapeutics MSTX

Healthcare Biotechnology
"Mast Therapeutics Inc is a biopharmaceutical company developing clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. Its product candidate, AIR001, a sodium nitrite solution for inhalation via nebulization."

Recent & Breaking News (NYSEAM:MSTX)

Savara Announces Closing Of Merger With Mast Therapeutics

PR Newswire April 27, 2017

Mast Therapeutics And Savara Announce Anticipated Merger Exchange Ratio

PR Newswire April 25, 2017

Mast Therapeutics Announces Adjournment Of Special Stockholders Meeting

PR Newswire April 21, 2017

Mast Therapeutics Announces Possible Adjournment Of Special Stockholders Meeting To Solicit Additional Votes For Merger With Savara

PR Newswire April 20, 2017

Mast Reminds Stockholders To Vote For The Proposed Merger With Savara

PR Newswire April 17, 2017

Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Mast Therapeutics Stockholders Vote "FOR" The Proposed Merger And Related Proposals

PR Newswire April 11, 2017

Mast Therapeutics And Savara Announce Approval To List Common Stock On The Nasdaq Capital Market

PR Newswire April 10, 2017

Mast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara

PR Newswire March 16, 2017

Biotech Stocks Under Scanner -- Gilead Sciences, Exelixis, Mast Therapeutics, and Novavax

PR Newswire March 14, 2017

Mast Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results

PR Newswire March 6, 2017

Mast Therapeutics Announces Clinical Study Of AIR001 For The Treatment Of Chronic Infection In Cystic Fibrosis Patients

PR Newswire March 6, 2017

Biotech Stocks Under Scanner -- Mast Therapeutics, MannKind, Celgene, and Opko Health

PR Newswire February 3, 2017

The Market In 5 Minutes: Earnings Results, Conferences, Trump And More

Benzinga.com  January 9, 2017

Mast Therapeutics And Savara Sign Merger Agreement

PR Newswire January 7, 2017

Mast Therapeutics Announces Initiation Of Patient Enrollment In Additional Phase 2 Study Of AIR001 For The Treatment Of Heart Failure With Preserved Ejection Fraction

PR Newswire December 6, 2016

Mast Therapeutics Provides Update On Strategic Direction

PR Newswire November 21, 2016

Mast Therapeutics Reports Third Quarter 2016 Financial Results

PR Newswire November 8, 2016

Positive Interim Results From Phase 2 Study Of AIR001 In Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction (PH-HFpEF) Published In Journal Of Clinical Investigation

PR Newswire November 3, 2016

Mast Therapeutics To Host Third Quarter 2016 Financial Results And Business Update Conference Call

PR Newswire November 1, 2016

Research Reports on Biotech Equities -- Mast Therapeutics, Array BioPharma, Galena Biopharma, and Clovis Oncology

PR Newswire October 31, 2016